Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying advanced solid tumors, which include types of cancer such as Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, and Renal Cell Carcinoma. The study is testing the safety and effectiveness of three medications: BGB-A425, LBL-007, and Tislelizumab. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to explore how well these medications work together in treating the mentioned cancers. The study is divided into different phases. Initially, the focus is on understanding the safety and how well patients tolerate the combination of BGB-A425 with Tislelizumab. Later, the study will also look at the combination of BGB-A425 and LBL-007 with Tislelizumab, as well as LBL-007 with Tislelizumab. The study aims to find the best dose that patients can handle without severe side effects.

Throughout the study, researchers will monitor patients for any side effects and measure how the cancer responds to the treatment. The study will also assess how the body processes these medications. This research is important for developing new treatment options for patients with these types of advanced cancers.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the study, participants will be informed about the trial's purpose, procedures, and potential risks and benefits. Consent will be obtained before any trial-related activities begin.

  2. Step 2

    Initial assessment

    Participants will undergo an initial assessment to confirm eligibility. This includes a review of medical history, a physical examination, and laboratory tests to ensure adequate organ function and overall health status.

  3. Step 3

    Phase 1: dose escalation

    In this phase, participants will receive a combination of BGB-A425 and tislelizumab through intravenous infusion. The goal is to determine the maximum tolerated dose. Participants will be closely monitored for any adverse effects.

  4. Step 4

    Phase 2: safety lead-in

    Participants will receive a combination of BGB-A425, LBL-007, and tislelizumab or LBL-007 with tislelizumab. The focus is on assessing safety and tolerability. Monitoring for adverse effects continues.

  5. Step 5

    Phase 2: dose expansion

    This phase evaluates the antitumor activity of the drug combinations. Participants will receive the recommended doses determined in earlier phases. The objective response rate will be assessed to evaluate the treatment's effectiveness.

  6. Step 6

    Ongoing monitoring

    Throughout the trial, participants will undergo regular assessments, including physical exams, laboratory tests, and imaging studies, to monitor health status and treatment response. Safety and tolerability will be continuously evaluated.

  7. Step 7

    End of trial

    Upon completion of the trial, participants will have a final assessment to evaluate overall health and any long-term effects of the treatment. Results will contribute to understanding the treatment's safety and effectiveness.

Who can join the trial?

8 criteria

  • Must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale, which means you should be fully active or have some symptoms but still be able to carry out light work.
  • Must have adequate organ function, meaning your vital organs like the liver and kidneys are working well enough.
  • For Phase 1 and Phase 2 Safety Lead-In: Must have advanced, metastatic, or unresectable solid tumors confirmed by tests. You should have already tried standard treatments, or no standard treatment is available or tolerated.
  • For Phase 2 Dose-Expansion: Must have one of the following confirmed solid tumors:
    • For head and neck cancer participants: Recurrent or metastatic head and neck squamous cell cancer that cannot be treated with surgery or radiation with the intent to cure.
    • For lung cancer participants: Locally recurrent or advanced non-small cell lung cancer.
    • For kidney cancer participants: Locally advanced or metastatic renal cell carcinoma with clear cell type.
    • Must be within the age range specified for the study.
    • Both male and female participants are eligible.

Who cannot join the trial?

10 criteria

  • Patients with other types of cancer not listed in the study.
  • Patients who have not reached the required age range for the study.
  • Patients who are not able to follow the study procedures or instructions.
  • Patients who are pregnant or breastfeeding.
  • Patients with severe or uncontrolled medical conditions that could interfere with the study.
  • Patients who have had another cancer treatment recently that might affect the study results.
  • Patients with known allergies to the study drugs or similar medications.
  • Patients who are participating in another clinical trial at the same time.
  • Patients with a history of certain heart conditions or diseases.
  • Patients with active infections that require treatment.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BGB-A425

    is a medication being tested to see if it can help treat advanced solid tumors. In this study, it is used together with other medications to see if it is safe and how well it works against cancer. The researchers are trying to find the best dose that patients can tolerate without too many side effects.

  • LBL-007

    is another medication being studied for its potential to treat advanced solid tumors. It is used in combination with other drugs to check its safety and effectiveness. The goal is to find out how well it works in fighting cancer and what dose is best for patients.

  • Tislelizumab

    is a medication that helps the immune system fight cancer. It is used in this study with other drugs to see if it can improve treatment for patients with advanced solid tumors. The researchers are looking at how safe it is and how well it works when used with the other medications in the trial.

What is already known about the treatment

  • BGB-A425

    BGB-A425 is administered as an injection and is currently being studied in clinical trials to assess its safety and effectiveness in treating advanced solid tumors, including head and neck squamous cell cancer, non-small cell lung cancer, and renal cell carcinoma. It is being tested in combination with other medications like tislelizumab to determine the best dose and to evaluate its potential to shrink tumors. BGB-A425 works by targeting specific proteins on cancer cells, helping the immune system recognize and attack these cells more effectively. It is classified as an immunotherapy drug, which means it helps the body's immune system fight cancer.

  • LBL-007

    LBL-007 is also given as an injection and is part of ongoing research to understand its role in treating advanced solid tumors, such as head and neck squamous cell cancer, non-small cell lung cancer, and renal cell carcinoma. This medication is being tested in combination with BGB-A425 and tislelizumab to find the most effective dose and to see how well it can help reduce tumor size. LBL-007 works by interacting with specific molecules on cancer cells, enhancing the immune system's ability to detect and destroy these cells. It falls under the category of immunotherapy, which supports the immune system in combating cancer.

  • Tislelizumab

    Tislelizumab is administered through an injection and is being evaluated in clinical trials for its effectiveness in treating various advanced solid tumors, including head and neck squamous cell cancer, non-small cell lung cancer, and renal cell carcinoma. It is used in combination with other drugs like BGB-A425 and LBL-007 to determine the best treatment approach and to assess its ability to improve tumor response. Tislelizumab functions by blocking a protein that prevents the immune system from attacking cancer cells, thereby boosting the body's natural defenses against cancer. It is classified as an immunotherapy, which aids the immune system in fighting cancer.

Investigated diseases

  • Head and Neck Squamous Cell Cancer

    This type of cancer originates in the squamous cells lining the moist surfaces inside the head and neck, such as the mouth, nose, and throat. It typically begins as a flat, thin cell layer and can develop into a tumor. As the disease progresses, it may invade nearby tissues and spread to lymph nodes in the neck. The cancer can further metastasize to other parts of the body if not managed. Symptoms often include a persistent sore throat, difficulty swallowing, and changes in voice. The progression can vary based on the location and size of the tumor.

  • Non-Small Cell Lung Cancer

    This is the most common type of lung cancer, accounting for a majority of cases. It begins in the tissues of the lungs and can grow into a large mass. As it progresses, it may spread to nearby lymph nodes and other organs. The disease often develops slowly, but its progression can accelerate if it spreads beyond the lungs. Symptoms may include a persistent cough, chest pain, and shortness of breath. The rate of progression can differ based on the subtype and stage at diagnosis.

  • Renal Cell Carcinoma

    This is a type of kidney cancer that originates in the lining of the small tubes in the kidney. It often begins as a single tumor within one kidney but can occur in both kidneys simultaneously. As the disease progresses, it may grow larger and invade nearby tissues or spread to other parts of the body. Symptoms can include blood in the urine, a lump in the abdomen, and unexplained weight loss. The progression of the disease can vary significantly among individuals.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2022-500694-14-00Protocol codeBGB-900-102Estimated enrolment358 patientsSponsorBeigene Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).